Tag: ACE2

An analysis links COVID-19 to brain microvascular injury and inflammation

The ongoing COVID-19 pandemic is caused by the severe acute respiratory syndrome-2 (SARS-CoV-2), an RNA virus that belongs to the family Coronaviridae.  According to research, coronavirus disease 2019 (COVID-19) patients often suffer from neurological disorders like strokes, lost taste or smell, memory loss, confusion, and delirium. By comparing the symptoms associated with other coronavirus infections,

Some heart medications may facilitate SARS-CoV-2 infection through increasing ACE2 receptor levels

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has continued to ravage much of the world since it first emerged in December 2019. An interesting poster, just presented at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics 2021, reports an association between the

Updated Moderna vaccines neutralize South African SARS-CoV-2 variant in mice

Researchers in the United States have conducted a pre-clinical study demonstrating the efficacy of two updated versions of the Moderna mRNA-1273 vaccine against variants of severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19). Study: Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

COVID19's cytokine storm ushers in a local complement storm in the lungs

A new study published in the journal Science Immunology analyzed lung epithelial cells from patients infected with COVID-19 and found the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces the complement system as a dangerous weapon for viral infection. The complement system is an extension of the innate immune system to recognize pathogens and remove

Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study

As new variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, fueling the continued spread of the coronavirus disease 2019 (COVID-19) pandemic, a new study offers encouragement. Released as a preprint on the bioRxiv* server, the study reports the protection offered by antibodies elicited by natural infection against the newer variants

How effective has Israel’s SARS-CoV-2 testing and vaccination campaign been against the UK variant?

Several genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have risen to prominence during the course of the coronavirus disease 2019 (COVID-19) pandemic, one of which is the UK variant – termed B.1.1.7 by the Centers for Disease Control and Prevention (CDC). This variant is associated with increased transmissibility compared to the wild-type

COVID-19 and lung cancer have a common pathway, say researchers

The coronavirus disease 2019 (COVID-19) is a transmissible viral disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for the ongoing global pandemic. The virus was first detected in Wuhan, China, at the end of 2019 and to date has caused over 109 million infections worldwide. With over 2.4 million